GMP News, GMP guidelines, GMP Violations, GMP warnings A Public Health Global News Portal

Welcome to www.seekgmp.com FDA, WHO, EU, TGA, CDSCO guidelines...and GMP Violations news/warning letters..

150000+ Industry Leaders already read it everyday

  • This is default featured slide 1 title

    Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

  • GMP Trends, Quality Tools

    Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

  • GMP News drifts on Market and economy

    Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

  • This is default featured slide 4 title

    Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

  • What to Ask Your Doctor Before Taking Opioids

    Every patient should ask questions when getting a new prescription. This is especially important when your doctor, dentist or other health care professional prescribes you an opioid, such as hydrocodone, oxycodone, codeine and morphine. What should you ask?

Showing posts with label Dr.Reddy's. Show all posts
Showing posts with label Dr.Reddy's. Show all posts

Wednesday, March 21, 2018

FDA has issued form 483 to Dr. Reddy's Laboratory | API | IDA Bollaram | GMP VIOLATIONS |


FDA has insured form 483  to Dr. Reddy's Laboratory | API | IDA Bollaram | GMP VIOLATIONS |








The US FDA has been inspected the Dr. Reddy's laboratory located at IDA Bollaram which is manufacturing of Active pharmaceutical ingredients. The form 483 has been issued with 5 observations.


OBSERVATION 1:
The responsibilities and procedures applicable to the Quality control unit are not fully followed. Specially 

      A)     Your quality unit failure to close multiple CAPAs within allowable timeframe and justification to extend the completion timeframe was not requested. Specifically, your quality unit did not request an extension to the few CAPAs.

      B)      One of QC laboratory Audit trail reviewed and found discrepancy which is having without logging incident. And proper justification found.

      C)      Failed to establish Quality agreements with starting materials suppliers

      D)     Failure to follow the Incident reporting system as per your site SOP.

OBSERVATION 2:
Procedures describing the handling of written and oral complaints related to API Materials are not followed.

     A)     In adequate closure of market complaint closure without tracking fulfillment.
     B)     Complaint investigation concluded with CAPA, no CAPA has logged and not implemented the            SOP revision.

OBSERVATION 3:
Building used in the manufacturing, processing, packing of API finished materials are not maintained in a good state of repair.
As the facility containment not meeting as required.

OBSERVATION 4:
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the quarantine storage of API finished materials prior to release.

OBSERVATION 5:
There is NO assurance that the equipment used in the production of ___ and ___API are always maintained and kept in under proper conditions for manufacturing operations and no prevent the contamination of the products.

A)     Failure to fulfil the record sheets as required
B)      A piece of fabric thread was  observes the inside the filled container

C)      Presence of product was observed inside the following production equipment.


www.gmpviolations.com GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed/ experts experiences sharing.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news. Please ensure the guideline as per Regulatory agencies.
Share:

Saturday, July 29, 2017

USFDA observations beneficial in long run: Dr Reddy's India

Since November 2015, the company has significantly invested in processes, automation, detailed documentation of each batch and standard operating procedures and further strengthened its quality management systems.


Mumbai: US health regulator's observations are "unmistakably" beneficial in the long run and have helped the company accelerate the pace of quality reforms, pharma major Dr Reddy's Laboratories has said.
"The remedial actions triggered by the USFDA observations are unmistakably beneficial to us in the long run and it has helped us accelerate the pace of quality reforms across our plants. We believe that the shift in the US regulator's approach from 'what has gone wrong' to 'what can go wrong' is for the long term good of the industry," Dr Reddy's Labs Chairman K Satish Reddy said in the company's annual report.
Based on its corrective actions, the USFDA reinspected the company's three plants between February and April 2017. It had received some observations from the regulator thereafter and subsequently submitted a detailed response. The company is awaiting the USFDA's views on its latest set of responses.
Since November 2015, the company has significantly invested in processes, automation, detailed documentation of each batch and standard operating procedures and further strengthened its quality management systems.
However, the warning letter put on hold the company's approval of several key drugs, including high value added injectables and complex generics, to the US from the last quarter of 2015-16 and throughout 2016-17. This pipeline blockage affected revenues, margins and profits. Additional costs of conducting remedial work, including the use of international consultants, also reduced profits, he added.
Going forward, the drugmaker believes that the pricing pressures in the US market will be less severe and more calibrated in 2017-18. "We also have an excellent pipeline of complex generics to be introduced to the country in 2017-18 and expect to do better through this effective upgrade of our portfolio mix," Reddy said.
"We also believe that there are enormous opportunities across emerging markets and are playing actively to increase our presence in these territories through complex generics and biosimilars. The Russian and CIS markets are on a moderate upswing," Reddy added.
According to the pharma major, in the domestic market, threats of government-induced pricing pressure remain. "We are seeing greater offtake of generics - both relatively simple and complex - and oncological biosimilars, the latter through greater hospital and institutional sales. We believe that emerging markets will again get back to double-digit growth. Despite government induced pricing pressures on pharmaceutical products, India remains a high growth market," stated the report.
In 2016-17, revenues grew by 9 per cent over the previous year.
The first quarter of 2017-18, the chairman said, may see a temporary decline in sales due to de-stocking by trade on implementation of the Goods and Services Tax (GST). "Post normalisation, we expect to grow in low double digits in 2017-18 and for the foreseeable future," Reddy said.

Source: Economic Times India

www.gmpviolations.com GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed/ experts experiences sharing.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news. Please ensure the guideline as per Regulatory agencies.
Share:

Wednesday, March 22, 2017

Dr.Reddy’s gets 13 observations from USFDA for Visakhapatnam plant


On Wednesday, shares of Dr.Reddy’s fell 0.04% to Rs2,851.40 on BSE, while the benchmark Sensex shed 0.34% to 28,901.94 points. Photo: Mint

On Wednesday, shares of Dr.Reddy’s fell 0.04% to Rs2,851.40 on BSE, while the benchmark Sensex shed 0.34% to 28,901.94 points. 

Mumbai: The US Food and Drug Administration (FDA) has made 13 observations relating to deviation from good manufacturing practices at Dr.Reddy’s Laboratories Ltd’s cancer formulations facility at Duvvada in Visakhapatnam, the company said in a stock exchange filing on Wednesday.
“The audit of our formulation manufacturing plant at Duvvada, Visakhapatnam, by the USFDA, has been completed today (8 March, 2017). We have been issued a Form-483 with 13 observations, which we are addressing,” the company said.
Dr.Reddy’s did not give details on nature of the observations.
The FDA issues a Form-483 if its investigators spot any conditions that in their judgment may constitute violations of the US Food Drug and Cosmetic (FD&C) Act and related laws.
“This is a negative development as the number of observations is high despite the remedial measures taken by Dr.Reddy’s after receiving the warning letter. Duvvada plant is newer but USFDA is very strict as far as injectables are concerned. I believe that remediation process will take at least one to one-and-a-half years and this will impact future product filings and approvals in the US,” said Surajit Pal, an analyst at Prabhudas Lilladher.
On 21 February, the company’s active pharmaceutical ingredients (API) manufacturing plant at Miryalaguda in Telangana was issued a Form-483 by the USFDA with three observations relating to violation of norms.
In November 2015, the Hyderabad-based drug maker had received warning letter from the USFDA for breach of norms at formulation plant at Duvvada, and API facilities at Miryalaguda and Srikakulam.
In mid-January, Dr.Reddy’s had said that “all the commitments as part of warning letter response have been completed and the three plants will be re-inspected by the US regulator by end of March.”
After receiving the warning letter, the pharmaceutical major submitted five responses to the USFDA at regular intervals, giving updates on the remedial work undertaken at the three plants. The company also hired an independent consultant to resolve the compliance issues at these units.
The warning letter had an adverse impact on the company’s earnings as new product approvals in the US from these sites were put on hold. The US market accounted for nearly half of Dr.Reddy’s total revenue of Rs15,470 crore in the year ended March 2016.
On Wednesday, shares of Dr.Reddy’s fell 0.04% to Rs2,851.40 on BSE, while the benchmark Sensex shed 0.34% to 28,901.94 points.

Source: Livemint: Isha Trivedi
www.gmpviolations.com
GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed/ experts experiences sharing.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news. Please ensure the guideline as per Regulatory agencies.
Share:

Wednesday, October 26, 2016

Dr Reddy's Q2 profit down 60 pc to Rs 31 cr

"We have made progress on remediation efforts and continue to work on addressing concerns of the regulator," DRL's Co-chairman and CEO G V Prasad said.



New Delhi, Oct 25: Dr Reddy's Laboratories today reported a decline of 60.12 per cent in consolidated net profit for the September quarter at Rs 30.89 crore, mainly because of drop in sales in Venezuela and North America.
The company had posted a net profit of Rs 77.47 crore in the July-September quarter of the previous fiscal, Dr Reddy's Laboratories (DRL) said in a filing to BSE.
DRL's total income from operation on consolidated basis was down 10.05 per cent to Rs 361.63 crore as against Rs 402.07 crore in the corresponding quarter last fiscal.
"All major businesses have shown sequential improvement over the previous quarter with revenues up 11 per cent and EBITDA 61 per cent. We have made progress on remediation efforts and continue to work on addressing concerns of the regulator," DRL's Co-chairman and CEO G V Prasad said.
Its total expenses was up 4.49 per cent to Rs 325.15 crore as against Rs 311.17 crore last year.
"Gross profit margin declined by 56 per cent ... primarily on account of lower sales due to increased competitive intensity in some of our key molecules in the US," the company said.
"Revenues from global generic segment was at Rs 29 billion, year-on-year decline of 12 per cent; decrease primarily on account of lower contribution from North America and loss of sales from Venezuela," it added.
In first half of the current fiscal, DRL's consolidated standalone net profit was down 67.48 per cent to Rs 46.24 crore as against Rs 142.22 crore in the six-month period a year ago.
Its total income in first half of the current fiscal was also down 11.96 per cent to Rs 686.10 crore compared to Rs 779.35 crore in the same period last year.
Shares of DRL were trading at Rs 3,115.60 on BSE during the morning trading hour, up 0.84 per cent from previous close.

www.gmpviolations.com (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.)

 Disclaimer: The Logos/Images posted here are belongs to respective to Authority / owners of firm.
Share:
Related Posts Plugin for WordPress, Blogger...

Popular Posts

Related Posts Plugin for WordPress, Blogger...

Subscribe Free GMP Guidelines

Enter your email address:

Delivered by FeedBurner

Followers

Printfriendly

Subscribe via email for free

Services

Enter your email address:

Delivered by FeedBurner

Contact Form

Name

Email *

Message *

Menu :
Powered by Blogger.

Visitors

    Translater

    Category

    2016 (37) 2017 (85) 2018 (10) 211 CFR (2) 211.63 (1) 21cfr (1) 483 (5) AAFA (1) Abbott (2) AboutUs (1) ALCOA (1) Alerts (2) ANDA (1) Anshu (2) Antibiotics (1) apic (1) APR17 (8) APS (2) Articles (4) AstraZeneca (1) Aug17 (2) Aurobindo (2) Author (2) Authors (8) Biocon (1) cadila (1) capa (3) CDSCO (5) Change control (1) Christian Green (1) cipla (2) Cleaning validation (1) Data Integrity (9) dec16 (15) Definations (1) Deviations (1) Donald Trump’s (2) Downloads (17) Dr.Reddy's (4) eca (1) EIR (1) Eli Lilly (1) ema (12) EU (9) FDA (73) FDA Guide (20) FEB17 (15) Genaral (1) General Health (2) GMP (1) GMP News (36) gsk (2) GuidelineEU (10) GuidelinesG (5) GuidelineW (2) GV/0117/001 (1) GVAuthors (3) Health (4) HOSPIRA (1) ICH (3) ICHGuide (3) import alert (1) India (1) ISPE (1) James Bullock (1) JAN17 (23) Jul17 (8) July17 (1) Jun17 (4) Lupin (2) Mahender (40) MAR17 (13) Mar18 (7) May17 (10) May18 (1) MHRA (3) MHRA guide (1) Mumbai (1) Mylan (4) Natco (1) News (55) Non Complinaces (1) Nov16 (5) Novartis (1) oct (1) Oct16 (10) OCT17 (1) PDA (1) Personnel (1) pfizer (1) pics (8) Picsguide (2) QbD (1) Quality Docs (1) RCA (1) Recall (1) safety (1) Sanjeev Kumar Singh (4) Sanofi (1) Sep16 (6) Siegfried Schmitt (2) SUN (1) TGA (3) TOP 10 PHARMA (1) USP (2) Validation (3) Warning Letters (44) WHO (6) zika (1)

    Sponsors

    Theme Support